Cefadroxil, a New Broad-Spectrum Cephalosporin
AUTOR(ES)
Buck, R. E.
RESUMO
Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential when administered orally. The inhibitory activity of this compound was similar to that of cephalexin and cephradine when tested against 602 clinical isolates on Mueller-Hinton medium. In the oral treatment of experimental infections of mice, cefadroxil was more effective than cephalexin against Streptococcus pyogenes, and comparably effective against Streptococcus pneumoniae, Staphylococcus aureus, and several gram-negative species. Administered orally to mice, at doses ranging from 25 to 100 mg/kg, cefadroxil attained peak concentrations in the blood similar to those of cephalexin. At a dose of 200 mg/kg, however, higher peak levels were noted with cefadroxil than with cephalexin. In regard to other properties which were investigated, the behavior of cefadroxil compared favorably to that of cephalexin.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=351975Documentos Relacionados
- Pharmacokinetics of Cefonicid, a New Broad-Spectrum Cephalosporin
- Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.
- In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.
- GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
- Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species